ALD

ALD Launches First-to-Market Balancing Chip for Supercapacitors Rated at 3.00 Volts or Higher Preventing Overvoltage Failures

Retrieved on: 
Monday, October 31, 2022

SUNNYVALE, Calif., Oct. 31, 2022 /PRNewswire-PRWeb/ -- Advanced Linear Devices Inc. (ALD), a design innovator in analog semiconductors, today announced an addition to the quad family of Supercapacitor Auto Balancing (SAB™) MOSFETS. The precision MOSFET array offers a simple, economical and effective method to balance and regulate supercapacitors rated at a higher voltage. The chip is built using ALD EPAD® proven production technology. The ALD810030 stabilizes supercapacitors that can be used in a wide variety of applications, such as actuators, telematics, solar panels, emergency lighting, security equipment, barcode scanners, advanced metering boxes and battery backup systems.

Key Points: 
  • SUNNYVALE, Calif., Oct. 31, 2022 /PRNewswire-PRWeb/ -- Advanced Linear Devices Inc. (ALD), a design innovator in analog semiconductors, today announced an addition to the quad family of Supercapacitor Auto Balancing (SAB) MOSFETS.
  • The precision MOSFET array offers a simple, economical and effective method to balance and regulate supercapacitors rated at a higher voltage.
  • The chip is built using ALD EPAD proven production technology.
  • "Once again, ALD's technology leadership has created a product that is always on for balancing larger supercapacitors that uses virtually no power," said Robert Chao, president and founder of ALD.

Forge Nano Appoints Don Kaiser as COO for Continued Advancement of Battery Technology Market

Retrieved on: 
Tuesday, October 18, 2022

He joins Forge Nano from previous roles at Aptiv and A123 Systems with vast experience that includes executive-level PE assignments for over 20 sites worldwide.

Key Points: 
  • He joins Forge Nano from previous roles at Aptiv and A123 Systems with vast experience that includes executive-level PE assignments for over 20 sites worldwide.
  • Forge Nano will leverage Don's expertise in the Lithium Ion Battery market to build the infrastructure needed to bring Forge Nano's next-gen Atomic Armor technology to the market.
  • "Forge Nano will capitalize on Don's experience building A123 battery factories globally and a long history in operational excellence," said Paul Lichty, CEO, Forge Nano.
  • Forge Nano is a global leader in surface engineering and precision nano-coating technology, using Atomic Layer Deposition (ALD).

Atomic Layer Deposition Global Market Report 2022: Rise in Demand for Solar Devices Drives Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, October 17, 2022

As cosmetics witness a higher demand, demand for atomic layer deposition increase, particularly as people try to move to nonpetroleum-based products.

Key Points: 
  • As cosmetics witness a higher demand, demand for atomic layer deposition increase, particularly as people try to move to nonpetroleum-based products.
  • A strong focus on personal grooming and good hygiene is propelling the cosmetics market growth, which in turn, is driving the global atomic layer deposition market growth.
  • Atomic layer deposition acts as a nonpetroleum product alternative for the cosmetics and personal care industry, which is expected to drive the global atomic layer deposition market growth.
  • Hence, the rise in demand for solar devices is expected to drive the target market growth over the forecast period.

Li-Ion Battery Cathode Performance and Cost Improvements Are Targeted by Forge Nano and Sylvatex in a New Collaboration

Retrieved on: 
Thursday, October 13, 2022

The collaboration facilitates the delivery of next-generation Li-ion battery CAM at a commercial scale in North America.

Key Points: 
  • The collaboration facilitates the delivery of next-generation Li-ion battery CAM at a commercial scale in North America.
  • Using less energy and water will overcome the problems of cathode manufacturing that limit battery manufacturers and OEMs today."
  • Sylvatex (SVX) is transitioning the world's energy systems through foundational manufacturing improvements impacting our zero-emission electric future and grid storage.
  • The Company has developed and is commercializing a lithium-ion battery cathode production technology that uses a sustainable, waterless manufacturing process.

Poxel Announces Upcoming Presentation at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference

Retrieved on: 
Thursday, October 13, 2022

POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it is presenting at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference on Monday, October 17th, 2022 at 10:00 am ET (4:00 pm CEST).

Key Points: 
  • POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that it is presenting at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference on Monday, October 17th, 2022 at 10:00 am ET (4:00 pm CEST).
  • Thomas Kuhn, CEO of Poxel, and other members of the Poxel management team will be available for one-on-one virtual meetings.
  • Typical risk factors for NASH include obesity, elevated levels of blood lipids (such as cholesterol and triglycerides) and type 2 diabetes.
  • Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders.

Poxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022

Retrieved on: 
Wednesday, October 12, 2022

The study also assessed the effects of PXL065 on liver histology and other metabolic and non-metabolic biomarkers.

Key Points: 
  • The study also assessed the effects of PXL065 on liver histology and other metabolic and non-metabolic biomarkers.
  • Analysis of histologic changes was based on paired liver biopsies in PXL065 vs. placebo-treated NASH patients before and after the 36-week treatment period.
  • Across all PXL065 treatment arms (pooled data), 39% of patients had fibrosis improvement by 1 stage without worsening NASH (%) vs. 17% with placebo.
  • For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1).

Availability of Poxel's 2022 Half-Year Financial Report

Retrieved on: 
Tuesday, October 4, 2022

POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic diseases, today announces the publication of its half-year financial report as of June 30, 2022.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic diseases, today announces the publication of its half-year financial report as of June 30, 2022.
    the consolidated financial statements for the first half of 2022 closed on June 30, 2022;
    the Statutory Auditors' limited review report on the half-year information, which includes several observations;
    the certificate of the person responsible for the half-year financial report.
  • Next financial press release: 2022 Third Quarter Financial Update, on November 8, 2022.
  • Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders.
  • For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1).

Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting

Retrieved on: 
Monday, October 3, 2022

The results of the analysis performed using the Finkelstein-Schoenfeld method of Win-Ratios (WR) demonstrated a statistically superior benefit when using ultrafiltration over diuretics for fluid-overloaded heart failure patients.

Key Points: 
  • The results of the analysis performed using the Finkelstein-Schoenfeld method of Win-Ratios (WR) demonstrated a statistically superior benefit when using ultrafiltration over diuretics for fluid-overloaded heart failure patients.
  • The results favored ultrafiltration over diuretics in reducing heart failure events within 30 days and cardiovascular mortality within 90 days.
  • Adjustable Ultrafiltration (AUF) was statistically superior compared to Adjustable IV Loop Diuretics (ALD) with 81% more wins (Win Ratio=1.81, p=0.0429).
  • Nuwellis is committed to making Aquadex therapy the standard of care for fluid management in heart failure patients that are unresponsive to diuretics.

Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA for Autosomal-Dominant Polycystic Kidney Disease (ADPKD)

Retrieved on: 
Monday, October 3, 2022

ADPKD is an inherited form of chronic kidney disease where the unmet need is high, with only one approved drug which is associated with significant safety-tolerability challenges.

Key Points: 
  • ADPKD is an inherited form of chronic kidney disease where the unmet need is high, with only one approved drug which is associated with significant safety-tolerability challenges.
  • The pathophysiology of ADPKD involves altered kidney metabolism and there is a strong rationale for AMPK activation as a therapeutic approach.
  • Autosomal dominant polycystic kidney disease (ADPKD) is the fourth leading cause of renal failure and the most common inherited cause of kidney disease.
  • 1 For more information on Orphan Drug Designation, see : https://www.fda.gov/industry/developing-products-rare-diseases-condition...
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221002005044/en/

ACM Research Launches New Furnace Tool for Thermal Atomic Layer Deposition to Support Advanced Semiconductor Manufacturing Requirements

Retrieved on: 
Tuesday, September 27, 2022

The Ultra Fn A system adds thermal atomic layer deposition (ALD) to ACMs extensive list of supported furnace applications.

Key Points: 
  • The Ultra Fn A system adds thermal atomic layer deposition (ALD) to ACMs extensive list of supported furnace applications.
  • The company also announced that it has shipped the first Ultra Fn A furnace tool to a top-tier China-based foundry manufacturer.
  • Our new ALD tool builds on our extensive furnace platform, which also includes support for atmospheric, low-pressure and ultra-high vacuum furnace options.
  • The Ultra Fn A furnace tool was designed from the ground-up to meet best-in-class requirements for high-throughput batch ALD processing.